- Conditions
- Obstructive Hypertrophic Cardiomyopathy (oHCM)
- Interventions
- Mavacamten
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 49
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Non-obstructive Hypertrophic Cardiomyopathy
- Interventions
- IMB-1018972, Placebo
- Drug
- Lead sponsor
- Imbria Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 13
- States / cities
- La Jolla, California • Los Angeles, California • San Francisco, California + 10 more
- Conditions
- Cardiomyopathy, Hypertrophic
- Interventions
- Mavacamten, Placebo
- Drug · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 580 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 36 more
- Conditions
- Cardiomyopathy, Hypertrophic
- Interventions
- Not listed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Hypertrophic Cardiomyopathy (HCM)
- Interventions
- CK-3773274 (5 - 15 mg), CK-3773274 (10 - 30 mg), Placebo for CK-3773274
- Drug
- Lead sponsor
- Cytokinetics
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 18
- States / cities
- Los Angeles, California • San Francisco, California • Evanston, Illinois + 13 more
- Conditions
- Cardiovascular Disease (CVD), Heart Failure, Aortic Stenosis, Aortic Stenosis Disease, Hypertension, Hypertension (HTN), Hypertrophic Cardiomyopathy Patients, Hypertrophic Cardiomyopathy Without Obstruction, Hypertrophic Cardiomyopathy, Obstructive, Dilated Cardiomyopathy (DCM), Dilated Cardiomyopathy, Dilated Cardiomyopathy, Familial
- Interventions
- Not listed
- Lead sponsor
- Prolaio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Obstructive Hypertrophic Cardiomyopathy
- Interventions
- Mavacamten, Non-mavacamten symptomatic oHCM therapy
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 60
- States / cities
- Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 48 more
- Conditions
- Obstructive Hypertrophic Cardiomyopathy (oHCM)
- Interventions
- Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg), Placebo to match aficamten, Metoprolol succinate (50 mg, 100 mg, 150 mg and 200 mg), Placebo to match metoprolol succinate
- Drug
- Lead sponsor
- Cytokinetics
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 28
- States / cities
- Anchorage, Alaska • Phoenix, Arizona • La Jolla, California + 21 more
- Conditions
- Hypertrophic Cardiomyopathy
- Interventions
- Eleclazine, Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 26
- States / cities
- Los Angeles, California • Stanford, California • New Haven, Connecticut + 16 more
- Conditions
- Obstructive Hypertrophic Cardiomyopathy
- Interventions
- mavacamten, Placebo
- Drug
- Lead sponsor
- MyoKardia, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 251 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 29
- States / cities
- Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 23 more
- Conditions
- Cardiomyopathy, Hypertrophic Obstructive
- Interventions
- BHB-1893, Metoprolol
- Drug
- Lead sponsor
- Braveheart Bio, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 4
- States / cities
- Burlington, Massachusetts • Manhasset, New York • Rock Hill, South Carolina + 1 more
- Conditions
- Hypertrophic Cardiomyopathy
- Interventions
- Not listed
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 177 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Hypertrophic Cardiomyopathy
- Interventions
- TN-201
- Genetic
- Lead sponsor
- Tenaya Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2032
- U.S. locations
- 10
- States / cities
- La Jolla, California • San Francisco, California • Atlanta, Georgia + 7 more
- Conditions
- Cardiopulmonary Failure, Myocardial Infarction (MI), Heart Decompensation, Heart Failure, HFrEF - Heart Failure with Reduced Ejection Fraction, HFpEF - Heart Failure with Preserved Ejection Fraction, Syncopation, Syncope, Ischemic Cardiovascular Disease, STEMI, STEMI (ST Elevation MI), Atrial Fibrillation (AF), Atrial Enlargement, LVF, Conduction Defect, Conduction Abnormalities, Heart Block, Valvular Diseases, Cardiac Output, Low, Stroke Volume, Stroke Volume Variation, Hyperkalemia, Hypercalcemia, Hypocalcemia, LV Dysfunction, QT Prolongation, Sudden Cardiac Death Due to Cardiac Arrhythmia, Ventricular Arrhythmia, Pacing, Pacing Induced Dyssynchrony, Silent Ischemia, Pericarditis, Sleep Related Breathing Disorder, RSA, Apnea, Obstructive, Cardiac Output Measurement, Respiratory Impedance, CRT And/or ICD, Infarction, Cardiomyopathies, Primary, Hypertrophy
- Interventions
- SUBPROTOCOL A, SUBPROTOCOL B, SUBPROTOCOL C, SUBPROTOCOL D, SUBPROTOCOL E, SUBPROTOCOL F, SUBPROTOCOL G, SUBPROTOCOL H
- Device
- Lead sponsor
- Peerbridge Health, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Melbourne, Florida
- Conditions
- Hypertrophic Cardiomyopathy (HCM), Cardiac Imaging, Echocardiography, Mavacamten, Obstructive Cardiomyopathy, Hypertrophic
- Interventions
- Not listed
- Lead sponsor
- UltraSight
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Hypertrophic Cardiomyopathy (HCM)
- Interventions
- Approved Hypertrophic Cardiomyopathy drug treatments, Mavacamten
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 331 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Hypertrophic Cardiomyopathy
- Interventions
- pacemaker implantation, percutaneous transluminal septal ablation (PTSA)
- Procedure
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2002
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
- Interventions
- Aficamten, Placebo
- Drug
- Lead sponsor
- Cytokinetics
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • La Jolla, California • Los Angeles, California + 46 more
- Conditions
- Hypertrophic Obstructive Cardiomyopathy, Thoracic Aortic Dilatation, Heart Disease Caused by Ionising Radiation, Quality of Life
- Interventions
- QOL Survey
- Other
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 380 participants
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Hypertrophic Cardiomyopathy
- Interventions
- Moderate Intensity Exercise Program
- Behavioral
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Pediatric, Symptomatic Obstructive Hypertrophic Cardiomyopathy
- Interventions
- Aficamten, Placebo
- Drug
- Lead sponsor
- Cytokinetics
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 20 more
- Conditions
- Non-obstructive Hypertrophic Cardiomyopathy
- Interventions
- Ninerafaxstat 200mg MR, Placebo
- Drug
- Lead sponsor
- Imbria Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 26
- States / cities
- La Jolla, California • Los Angeles, California • San Francisco, California + 21 more
- Conditions
- Diabetic Retinopathy, Macular Degeneration, Glaucoma, Retinitis Pigmentosa, Vision Disorders, Acute Coronary Syndrome, Implantable Defibrillator User, Congestive Heart Failure, Hypertrophic Obstructive Cardiomyopathy, Orthostatic Hypotension, Syncope, Presyncope, Narcolepsy, Dementia, Multiple Sclerosis, Parkinson Disease, Brain Injuries, Spinal Cord Injuries, Stroke, Vertigo, Dizziness, Seizures, Substance Use, Insulin Dependent Diabetes Mellitus, Arthritis, Foot--Abnormalities, Chronic Obstructive Pulmonary Disease, Obstructive Sleep Apnea, End Stage Renal Disease, Sleep Apnea, Insomnia, Restless Legs Syndrome
- Interventions
- Driving Decision Aid, Older Drivers Website
- Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 529 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 3
- States / cities
- La Jolla, California • Aurora, Colorado • Indianapolis, Indiana
- Conditions
- Hypertrophic Cardiomyopathy
- Interventions
- mavacamten
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • New Haven, Connecticut • Durham, North Carolina + 1 more